Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary George Mason University Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that George Mason University in Fairfax, Va.
View HTML
Toggle Summary Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China
PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a
View HTML
Toggle Summary NIH Sponsored Study at Stanford University School of Medicine to Utilize Fluidigm Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay to Evaluate Immune Responses in Pediatric Patients with COVID-19
Researchers Seek Insight into Development and Progression of Multisystem Inflammatory Syndrome in Children Study Exemplifies Increasing Use of CyTOF Technology in Clinical Research SOUTH SAN FRANCISCO, Calif. , Feb. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
View HTML
Toggle Summary Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in investor meetings at
View HTML
Toggle Summary Helix Specialty Diagnostics Partners with Genomic LTC DX to Provide COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
Major Midwest Labs Targeting 3,000 Tests per Day SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Helix Specialty
View HTML
Toggle Summary Fluidigm Receives CE-IVD Mark for Its Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
SOUTH SAN FRANCISCO, Calif. , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its Advanta™ Dx
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 financial results
View HTML
Toggle Summary New Data Published in Gastroenterology Demonstrate the Power of Fluidigm’s Imaging Mass Cytometry on the Hyperion Imaging System to Identify Novel Targets for Pancreatic Cancer Therapy
Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for  Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center SOUTH SAN FRANCISCO, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors
SOUTH SAN FRANCISCO, Calif. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K.
View HTML
Toggle Summary Key Regulatory Body in India Grants Commercial License for Fluidigm Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay
Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India SOUTH SAN FRANCISCO, Calif. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive
View HTML